Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down22.050 -0.300 (-1.342%)
Research Report

22/02/2021 13:54

{I-bank focus}UOBKH lifts Ali Health (00241) to HK$31

[ET Net News Agency, 22 February 2021] UOB Kay Hian lifted its target price for Alibaba
Health Information Technology (00241) to HK$31 but downgraded its rating to "hold" from
"buy" after the recent rally.
The research house expects Ali Health to report strong revenue and adjusted earnings
growth of 75.4% and 272% respectively in FY2021. The company has achieved a turnaround
from loss to profit in 1H FY2021 and continues to experience substantial expansion with
improving profitability.
UOBKH said Ali Health's prescription drug sales business has achieved rapid growth and
has become a new driver of long-term sustainable growth. Meanwhile, the company has
launched the "Dr. Deer" app and aims to provide professional and reliable healthcare
services with extensive online and offline networks.
UOBKH estimated Ali Health will continue to deliver robust revenue growth of 56.9% CAGR
in FY2021-23. (KL)

Remark: Real time quote last updated: 12/04/2021 11:51
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.